Clinical Trials on In Development for Cystic Fibrosis in Australia

Total 269 results

Arrowhead Pharmaceuticals

Terminated

Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

Cystic Fibrosis, Pulmonary

Australia, New Zealand
Cystetic Medicines, Inc.
DevPro Biopharma

Recruiting

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People With Cystic Fibrosis (ABCI)

Cystic Fibrosis

Australia, New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, France, Spain, Belgium, Canada, Austria, Australia, Germany, United Kingdom, Denmark
Novartis Pharmaceuticals

Completed

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Pulmonary Infections | Pseudomonas Aeruginosa in Cystic Fibrosis

United States, Italy, Germany, France, Australia, Canada, Spain, Hungary, Mexico, Argentina
Flatley Discovery Lab LLC

Completed

A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Bayside Health

Unknown

Modified Release Posaconazole in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
The Alfred

Unknown

CPET in CF Patients With One G551D Mutation Taking VX770

Cystic Fibrosis

Australia
Gilead Sciences

Completed

Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis

Australia
The Alfred

Unknown

A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (CISTIC)

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Gilead Sciences

Withdrawn

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis | Mucociliary Clearance

Australia
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Cystic Fibrosis (CF)

United States, Australia, Belgium, Hungary, Netherlands, New Zealand, Slovakia, United Kingdom
The University of Queensland
Telethon Kids Institute

Completed

Prevention of Bronchiectasis in Infants With Cystic Fibrosis (COMBATCF)

Bronchiectasis | Cystic Fibrosis

Australia, New Zealand
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Completed

Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation

Cystic Fibrosis

Australia
AlgiPharma AS
AlgiPharma Australia Pty. Ltd.

Unknown

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Krystal Biotech, Inc.
Novotech (Australia) Pty Limited

Withdrawn

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Cystic Fibrosis

Australia
Indiana University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Viral Pathogenesis of Early Cystic Fibrosis Lung Disease (Early CF)

Cystic Fibrosis

United States, Australia
FH Campus Wien, University of Applied Sciences

Completed

SensoGrip - a Pressuresensitive Writing System (SensoGrip)

Developmental Delay in Fine Motor Function (Disorder)

Austria
Pharmaxis

Completed

A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis

Cystic Fibrosis

Australia, New Zealand
Respirion Pharmaceuticals Pty Ltd

Recruiting

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Pseudomonas Aeruginosa | Cystic Fibrosis Lung | Respiratory Infections, Recurrent, Chronic

United States, Australia
Savara Inc.
INC Research Limited

Completed

Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

Healthy | Cystic Fibrosis

Australia
The Alfred
Monash University

Recruiting

The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis. (A-STEP)

Fibrosis | Lung Diseases | Pancreatic Diseases | Cystic Fibrosis | Genetic Diseases | Respiratory Diseases

Australia
Pharmaxis

Completed

Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients (DPM-PK-102)

Cystic Fibrosis

Australia, United Kingdom
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Unknown

Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Cystic Fibrosis

Australia
Eloxx Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Cystic Fibrosis

Israel, Australia, Germany
AOP Orphan Pharmaceuticals AG

Completed

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

Cystic Fibrosis

Austria
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Australia
Sydney Children's Hospitals Network
Children's Hospital Colorado; Women's and Children's Hospital, Adelaide; John... and other collaborators

Completed

Cystic Fibrosis - Insulin Deficiency, Early Action (CF-IDEA)

Diabetes | Cystic Fibrosis

Australia, United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

Australia
Bayside Health
Monash University; The Alfred

Unknown

The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation

Cystic Fibrosis

Australia
Gilead Sciences

Terminated

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Cystic Fibrosis

France, Germany, Spain, United Kingdom, Australia
Proteostasis Therapeutics, Inc.

Completed

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Healthy Volunteer - Complete | Cystic Fibrosis - Complete

United States, Belgium, United Kingdom, France, Germany, Canada, Denmark, New Zealand, Australia
Bayside Health
The Alfred

Unknown

Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease

Asthma | Cystic Fibrosis | Bronchiolitis Obliterans | Lung Transplantation

Australia
Pharmaxis

Completed

Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study

Cystic Fibrosis

Ireland, United Kingdom, Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Australia, United Kingdom
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Austria, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Belgium, Spain, Australia, Canada
Neovii Biotech

Completed

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Bronchiectasis | Idiopathic Pulmonary Fibrosis | Cystic Fibrosis | Chronic Obstructive Pulmonary | Pulmonary Vascular Disease

United States, Australia, Austria, Canada
Flatley Discovery Lab LLC

Completed

A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

Cystic Fibrosis

United Kingdom, Australia, Germany, Czechia
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1)

Cystic Fibrosis

United Kingdom, Australia, Ireland, Germany, Czech Republic
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Galapagos NV

Completed

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Cystic Fibrosis

Ireland, United Kingdom, Belgium, Australia, Czechia, Germany
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION)

Cystic Fibrosis

United States, Australia, Canada, France, Germany, Ireland, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany

Clinical Trials on In Development for Cystic Fibrosis in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations